Squarepoint’s Medline Inc MDLN Stock Holding History

Squarepoint’s Portfolio MDLN Stock Details MDLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.12M	Buy	+32,400	New	+$1.19M	﹤0.01%	2678

Other funds holding MDLN

Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return

H&F Corporate Investors X San Francisco, California $2.46B AUM 15.37% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return

Squarepoint's MDLN Position: Q3 2026 in Review

Squarepoint sold out of Medline Inc (MDLN) in Q3 2026, closing a stake of 5,412 shares — an estimated $198K sold.

Squarepoint first reported a position in MDLN in Q4 2025 and held it in 2 quarters. The position peaked at $79.8M in Q4 2025. 315 funds tracked by Wall St. Rank hold MDLN as of Q3 2026.

Squarepoint reported no remaining Medline Inc position as of Q3 2026 after selling out during the quarter.
Squarepoint sold 5,412 Medline Inc shares in Q3 2026, an estimated $198K.
Squarepoint first reported a position in Medline Inc in Q4 2025 and held it in 2 quarters.
Squarepoint's Medline Inc position peaked at $79.8M in Q4 2025.
315 funds tracked by Wall St. Rank held Medline Inc as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.